What makes a great year for takeovers?
The number of biopharma buyouts overall last year did not rise, though more deals were struck in the “sweet spot”, and premiums saw a healthy rise.
A big finish confirms 2019 as a takeover year to remember
Two megamergers meant that 2019 was always going to be a big year for biopharma M&A in dollar terms – and then came a late flurry of deals.
The big cap empire strikes back
If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.
Vantage 2020 Preview – what’s in store for the biopharma sector?
Available to download for free now, our annual preview takes a data-driven look at 2020. Uncover biopharma’s biggest growth drivers, and see where the money is flowing.
Gene therapy clinical holds take centre stage
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.
The other shoe drops for Gossamer’s GB001
Novartis’s similarly acting fevipiprant had failed in asthma in October, and today it fails in the more important severe setting.
Ash 2019 – former Celgene holders look anxiously at contingent value
Celgene CVR holders have been desperate to find out whether JCAR017 is approvable. Yesterday at Ash they got their answer... kind of.
Ash 2019 – Roche doesn’t disappoint with bispecific
The first in-depth look Roche’s anti-CD20 bispecific, mosunetuzumab, reveals some very encouraging response rates, even in patients who failed Car-T therapy.
Global Blood’s sickle cell approval is no guarantee of success
Rather than nipping at Adakveo’s heels, Global Blood Therapeutics’ newly approved sickle cell drug Oxbryta might end up floundering in the Novartis product’s wake.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.